A best evidence topic in vascular and endovascular surgery was developed according to a structured protocol. The question addressed was whether treatment of infra-inguinal arterial occlusive disease with drug-eluting stents (DESs) provides improved outcomes compared with bare metal stents (BMSs) or percutaneous balloon angioplasty (PTA) alone. Altogether, 136 papers were found using the reported searches, of which 5 provided the best evidence to answer the question. All papers represent either level 1 or 2 evidence. The authors, journal, date, country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Main outcome measures varied among the studies, and included patency, in-stent restenosis, target lesion revascularization, major adverse events, clinical improvement and limb salvage. Evidence on the comparative efficacy of DESs in femoro-popliteal arterial disease is mainly based on two randomized, controlled trials. Paclitaxel-eluting stents were evaluated in the Zilver PTX trial and demonstrated superior 2-year results to either BMSs or PTA, as indicated/shown by patency (DES vs PTA, 74.8 vs 26.5%, P < 0.01), clinical benefit (DES vs PTA, P < 0.01) and event-free survival (DES vs PTA, 86.6 vs 77.9%, P = 0.02). However, the SIROCCO trial found that the sirolimus-eluting stent did not exhibit statistically significant differences in 2-year in-stent restenosis (22.9 vs 21.1%) and target lesion revascularization (6 vs 13%) compared with the BMS. Treatment of infra-politeal arterial disease with DESs was related with superior outcomes to those of BMSs, as indicated/shown by patency, freedom from target lesion revascularization and freedom from major adverse events. Furthermore, the ACHILLES trial, the only published trial comparing the infra-popliteal DES with PTA, revealed lower angiographic restenosis (22.4 vs 41.9%, P = 0.019) and greater vessel patency (75 vs 57.1%, P = 0.025) in the DES group at 1 year. However, data related to clinical parameters in patients with critical limb ischaemia secondary to infrageniculate arterial disease, such as limb salvage and ulcer healing, are insufficient. In conclusion, treatment of infra-inguinal arterial disease with DES is safe and seems to be superior to treatment with PTA alone or BMS. The role of DES in sustained improvement in clinical outcome end-points, such as limb salvage, remains to be elucidated.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This protocol has been previously fully described in the ICVTS [1] .
THREE-PART QUESTION
In [ patients with infra-inguinal arterial occlusive disease amenable to percutaneous intervention with balloon angioplasty/stenting] does [treatment with drug-eluting bare stents (DES)] provide [improved outcomes, as indicated/shown by sustained patency and limb salvage]?
CLINICAL SCENARIO
In a vascular outpatient clinic, you review a 56-year old diabetic man who presents with a non-healing necrotic ulceration on the tip of the big toe. This followed a minor trauma that he sustained 3 weeks previously. He is a mechanical engineer by profession. He has been investigated with magnetic resonance angiography (MRA), which revealed a 6.5 cm long chronic occlusion of the mid-superficial femoral artery and another short occlusion in the proximal portion of the anterior tibial artery. You explain the benefits of percutaneous intervention in the form of balloon angioplasty with or without stenting as a limb salvage procedure. He mentions that, recently, while surfing the Internet, he came across the news release of a medical journal reporting promising results with drug-releasing stents in the leg arteries, and is asking whether such treatment would be in his best interest. As a consultant vascular surgeon, you undertake to review the literature and discuss the case in the multidisciplinary team meeting. 
SEARCH STRATEGY

SEARCH OUTCOME
One hundred and thirty-six papers were found using the reported search. Five of these articles provided best evidence to answer the question [2] [3] [4] [5] [6] . These are presented in Tables 1 and 2 .
RESULTS
Femoro-popliteal disease
The first randomized, controlled trial (RCT) to investigate outcomes of DESs in atherosclerotic femoro-popliteal disease was the SIROCCO trial [2] . Ninety-three patients with lower limb arterial disease classified as Rutherford category 1-4 and Transatlantic Inter-Society Consensus (TASC) type C were randomized to receive treatment with either a sirolimus-eluting stent or a bare metal stent (BMS) (SMART, Cordis, Johnson & Johnson, Miami Lakes, FL, USA). The in-stent restenosis rate through 2 years, as documented by Duplex Ultrasound, was not significantly different between the DES and BMS groups (23 vs 21%, P = 1.00). Target lesion revascularization was similar in the two groups.
The 2-year follow-up outcomes of the Zilver PTX RCT, an industry-sponsored study evaluating paclitaxel-eluting stents (Zilver PTX, Cook Medical, Bloomington, IN, USA) in femoro-popliteal lesions, were recently published [3] . Patients with femoro-popliteal Clinical benefit 2-year event-free survival a : DES group: 87% PTA group: 78% (log-rank P = 0.02) 2-year primary patency: DES group: 75% PTA group: 27% (log-rank P <0.01) 2-year primary patency: Provisional DES group: 83% Provisional BMS group: 64% (log-rank P <0.01) 2-year clinical benefit b higher in DES than PTA (log-rank P <0.01) 2-year clinical benefit b higher in DES than BMS (log-rank P = 0.05) Industry-sponsored trial DES treatment for femoropopliteal arterial disease is safe DES treatment provides clinical outcomes superior to PTA or BMS DES: drug-eluting stent; PTA: percutaneous balloon angioplasty; BMS: bare metal stent; RCT: randomized, controlled trial. disease were randomized to receive either primary DES treatment (236 patients) or percutaneous balloon angioplasty (PTA) (238 patients). Patients with failed balloon angioplasty were subsequently randomized to provisional DES (61 patients) or BMS (59 patients) treatment. The main outcome end-points included event-free survival (defined as freedom from major adverse events, such as death, amputation, target lesion revascularization, limb ischaemia requiring surgical intervention and freedom from worsening of the Rutherford classification) and primary patency. The event-free survival rate through 2 years was significantly higher in the DES than that in the PTA group. Furthermore, the 2-year primary patency rate of 75% for the primary DES group was significantly superior to the 27% for the PTA group. Moreover, patients with failed PTA provisionally treated with DESs exhibited significantly higher 2-year primary patency than those treated with BMSs (83 vs 64%).
Infra-popliteal disease
A systematic review investigated the endovascular treatment of infra-popliteal arterial occlusive disease with DES [4] . Four RCTs and two observational studies comparing treatments with DES (287 patients) and BMS (257 patients) entered meta-analysis models. At 1 year, patients who received treatment with DESs had significantly higher primary patency, freedom from target lesion revascularization and clinical improvement than those treated with BMSs; however, limb salvage was not different between the groups.
Rastan et al. have published the long-term results of treatment with sirolimus-eluting stents when compared with treatment with BMSs for infra-popliteal arterial disease [5] . One hundred and sixtyone patients with peripheral arterial disease, classified as Rutherford category 3-5, were randomly assigned to receive DESs (82 patients) or BMSs (79 patients). The mean follow-up period for the DES and BMS group was 1005 ± 139 and 1027 ± 123 days, respectively. The event-free survival rate, defined as freedom from target lesion revascularization, major and minor index-limb amputation, myocardial infarction and death, was significantly higher in the DES group (log-rank P = 0.02). Limb salvage was similar in the two groups (99 vs 95%, P = 0.17), and clinically driven target-vessel revascularization occurred in 9% of the DES and 20% of the BMS patients (P = 0.06).
As opposed to comparison of DES and BMS, the ACHILLES trial compared outcomes of balloon angioplasty with those of sirolimus- eluting stents (CYPHER SELECT, Cordis, Johnson & Johnson, Bridgewater, NJ, USA) in patients with infra-popliteal arterial occlusive disease [6] . Patients with lower limb arterial disease, Rutherford category 3-5, were randomized to DES treatment (99 patients) or PTA (101 patients). The angiographic restenosis rate at 1 year was lower in the DES than the PTA group (P = 0.019). Furthermore, vessel patency was significantly higher in the DES than the PTA group (P = 0.025). No significant differences in clinically driven target lesion revascularization (P = 0.257) and index-limb amputation (P = 0.307) between DES and PTA patients were found.
CLINICAL BOTTOM LINE
Evidence on the efficacy of DES in femoro-popliteal arterial disease is mainly based on two RCTs [2, 3] . Paclitaxel-eluting stents seem to be associated with superior medium-term outcomes to those of either PTA or BMSs, as indicated/shown by primary patency, clinical benefit and freedom from major adverse events. Inconclusive evidence regarding the sirolimus-eluting stent exists, with a single RCT having found similar in-stent restenosis and target lesion revascularization in patients treated with DES or BMS [3] . More solid evidence with regard to the efficacy of the DES in infra-popliteal arterial disease has been identified. DESs have demonstrated improved patency and freedom from target lesion revascularization compared with BMSs or PTA; however, the effect on clinical outcome parameters, such as limb salvage and wound healing, remains unidentified. I read with great interest the position paper by Antoniou and colleagues [1] reviewing the data on endovascular treatment of infra-inguinal arterial disease comparing drug-eluting stents (DES) versus percutaneous transluminal angioplasty (PTA) with or without adjunctive bare metal stents (BMS). Over a 14-year period from January 2000 to October 2013, their literature search of specific query terms yielded 136 papers of which 5 provided the best evidence to answer the question posed. Related articles and references were also screened for suitable articles. As necessary, the data is separated into femoral-popliteal disease and infra-popliteal disease.
The two major randomized controlled trials usually referenced for femoral-popliteal disease include the SIROCCO trial (with sirolimus as the active drug) and the Zilver PTX trial (using paclitaxel). Although the former failed to demonstrate a statistically significant difference between DES using sirolimus and BMS [2] , the latter showed a primary patency of 75% in patients with the Zilver PTX (Cook Medical, Bloomington IN, USA) as compared to 27% with PTA, and a provisional 2-year primary patency of 83% with DES compared to 64% with BMS which was statistically significant concluding that DES treatment with the Zilver PTX provided superior outcomes with regard to the outcomes of event-free survival and primary patency compared to PTA or BMS [3] .
In the infra-popliteal segment, data has demonstrated that at 1 year, patients with DES had a significantly higher primary patency, freedom from target lesion revascularization and clinical improvement than those with BMS, however, the ultimate outcome of limb salvage was not different between these groups. The three multicentre randomized controlled trials included in a recent qualitative analysis and quantitative data synthesis are the YUKON-BTX (using sirolimus), DESTINY (using everolimus), and ACHILLES (using sirolimus) trials [4, 5] . These trials had several differences among them, namely the inclusion of only patients with critical limb ischaemia in the DESTINY trial as compared to both claudicants and patients with critical limb ischaemia in YUKON-BTX and ACHILLES; furthermore, ACHILLES included a greater proportion of patients with tibial chronic total occlusions compared with the other two. The pooled estimates have shown that primary DES placement for focal infra-popliteal lesions significantly improved primary patency, increased overall event-free survival and decreased the need for repeat procedures [4, 5] . The ultimate outcome of patient survival and limb salvage, however, demonstrated no significant differences. It should also be noted that these trials were not powered for these outcome measures.
Translating these data for both femoral-popliteal and infra-popliteal lesions into the clinical environment must be exercised with caution. Although Antoniou and colleagues present a case with a TASC II B lesion, the above trials evaluate short segment focal lesions that are not the majority of patients seen in everyday practice; more commonly seen patients usually involve complex, multiple and sequential lesions.
Although multiple and tandem stenoses or occlusions may be treated percutaenously, Katsanos and colleagues in their meta-analysis of infra-popliteal DES should be commended on their foresight that "in the absence of randomized data about longer infra-popliteal lesions, it may be frivolous and unwise to extrapolate the reported results [of their meta-analysis] to the setting of long tibial obstructions that require multiple DES placement with still unproven clinical-and cost-effectiveness" [5] . The option and durability of primary open infra-inguinal bypass must be considered in the treatment algorithm of multi-segmental lower extremity arterial disease. And in an era of increasing health care economics, cost-containment, and clinical outcomes, qualityof-life metrics and cost-utility parameters must be critically evaluated.
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